© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to July
first-in-class, bioavailable BCL-XL inhibitor
oral efficacy in xenograft, led to ADC dev.
from SBDD of prior BH3 mimetics
ACS Med. Chem. Lett., Jul. 5, 2020
AbbVie, North Chicago, IL / Genentech
A-1331852 is a highly potent, orally bioavailable inhibitor of BCL-XL, blocking a protein-protein interaction resulting in tumor cell apoptosis. The compound was an important tool compound for understanding the…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.